Document 0501
 DOCN  M9490501
 TI    Levels of dapsone and pyrimethamine in serum during once-weekly dosing
       for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic
       encephalitis.
 DT    9411
 AU    Opravil M; Joos B; Luthy R; Division of Infectious Diseases, University
       Hospital, Zurich,; Switzerland.
 SO    Antimicrob Agents Chemother. 1994 May;38(5):1197-9. Unique Identifier :
       AIDSLINE MED/94346835
 AB    Concentrations of dapsone, monoacetyldapsone, and pyrimethamine were
       determined in 36 serum samples from human immunodeficiency
       virus-infected patients on prophylaxis with once-weekly administration
       of dapsone-pyrimethamine (200 mg of dapsone-75 mg of pyrimethamine).
       During day 1 after ingestion, median levels of 1,038 ng of dapsone per
       ml and 356 ng of pyrimethamine per ml were found. During days 6 to 7,
       the dapsone level fell to < 20 ng/ml in five of nine serum samples, but
       the pyrimethamine level remained elevated (125 ng/ml). Concurrent, but
       separately ingested, didanosine administration did not seem to decrease
       the drug concentrations.
 DE    Adult  Aged  Dapsone/ANALOGS & DERIVATIVES/ADMINISTRATION &
       DOSAGE/*BLOOD/  *THERAPEUTIC USE  Drug Interactions  Female  Human  HIV
       Infections/COMPLICATIONS/*METABOLISM  Male  Middle Age  Phenotype
       Pneumonia, Pneumocystis carinii/*PREVENTION & CONTROL
       Pyrimethamine/ADMINISTRATION & DOSAGE/*BLOOD/*THERAPEUTIC USE  Support,
       Non-U.S. Gov't  Toxoplasmosis, Cerebral/*PREVENTION & CONTROL
       Zidovudine/ADVERSE EFFECTS/THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).